2. confidential2
The issues of cure
ā² Drugs and medical devices become more advanced, but
still pose challenges
ā² Another issue is suboptimal handling of the device
ā² Current issues are:
ā² Complex diseases with a variety of causes and treatments
ā² Overmedication (of antibiotics)
ā² Extensive cure need due to hospitalization
3. confidential3
Mission
ā² Improve the treatment options for patient and surgeon
ā² Improved working
ā² Longer efficacy (degradation)
ā² Target release
ā² Enhanced handling
ā² Better applicators
ā² Extension application areas
ā² Change functional form
4. confidential4
Elements as innovation
ā² New technologies offer new treatment solutions
ā² Biopolymers are used as devices or carriers for drugs or
tissues: viscosupplements and hemostasis products
ā² BioMed Elements has a technology platform to optimize
the behavior of medical devices by tuning the basic
elements of the polymers
6. confidential6
Biomaterials market
Market Size CAGR
Biomaterials 70 B 16%
Plastic surgery 6,5 B 14%
Orthopaedic 22 B 5%
Dental 6,6 B 7%
Hemostasis 1,5 B 4%
Tissue engineering 2,1 B 10%
The key market players are Royal DSM, Wright Medical Technology, Inc., Corbion
N.V., Zimmer Biomet Holdings, Inc., Bayer AG, Carpenter Technology Corporation,
Covalon Technologies Ltd., BASF SE, Invibio Ltd., Berkeley Advanced Biomaterials,
Inc., and Collagen Matrix, Inc. among others.
http://www.biomatin.eu/pdf/Regional_analysis_of_the_biomaterial_market.pdf
http://providencehightech.com/biomaterials-trends-forecasts/
7. confidential7
BioMed Core Technology
Source Material Core Technology Spherical Submicron Particles
ā² Access to well defined spherical submicron particles
ā² Control over parameters (e.g. size, density)
ā² Patented continuous process:
ā² Upscaling is possible
ā² High consistent quality
1Āµm
8. confidential8
Functional Forms
Suspension Powder GelSponge
Resorbable HemostatResorbable Scaffold Flowable Carrier
Application: Application: Application:Application:
Drug Carrier
Application Areas: orthobiologics, wound management, tissue engineering,
medical aesthetics and cosmetics.
9. confidential9
Business model
ā² Contract research and co-development:
ā² Feasibility study and product optimization
ā² Analytical study
ā² Contract manufacturing:
ā² Medical devices and half fabricates manufacturing
ā² Development own product range:
ā² Developing a range of niche products
10. confidential10
Value proposition
Phase 1:
Feasibility study for
improved or new
product
Phase 2:
Proof of concept;
lock in of IP
Phase 3:
Upscaling of
manufacturing
based on BioMed
expertise and
manufacturing
capabilities
Phase 4:
Manufacturing and
distribution of
device
11. confidential11
Current partners
ā² Netherlands: HCM Medical, Avivia, Fibriant, Leader
Biomedical and Zuyderland hospital.
ā² Europe: Mathys Medical (Switzerland), OST
Developpement (France) and Sirakoss (United Kingdom).
ā² USA: Pro-Tech Design, Alamo Tissue Services, Synergy
BioMedical, Celling Biosciences and Vivex Biomedical.
14. confidential14
Doās and donāts
ā² Be stubborn, but also look for people who are even more
stubborn
ā² Be smart on how to persuade investors
ā² Hold perspective on success; by yourself as well as from
others
ā² Use network opportunities
ā² Luck = your effort + what others help you with
15. confidential15
BioMedās future
ā² Investment need for validation of haemostatic gel
ā² Set up and strengthen partner network
ā² Perform animal study for heavy bleedings product Q2
2018
ā² Market access in ENT surgery products
And what the future brings